A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

Purpose: To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection of recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD) and geographic atrophy (GA). Design: Phase I sing...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Arshad M. Khanani, MD, MA, Raj K. Maturi, MD, Nika Bagheri, MD, Benjamin Bakall, MD, PhD, David S. Boyer, MD, Stephen S. Couvillion, MD, Dilsher S. Dhoot, MD, Nancy M. Holekamp, MD, Karim N. Jamal, MD, Dennis M. Marcus, MD, Dante Pieramici, MD, Aamir A. Aziz, BS, Kiran C. Patki, MD, William Z. Bridges, Jr., MD, Samuel B. Barone, MD
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2022-06-01
Schriftenreihe:	Ophthalmology Science
Schlagworte:	Age-related macular degeneration Complement factor H Complement regulation GEM103 Geographic atrophy
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S2666914522000434
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!